Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
Concetta Di Mauro,Ada Pesapane,Luigi Formisano,Roberta Rosa,Valentina D’Amato,Paola Ciciola,Alberto Servetto,Roberta Marciano,Roberta Clara Orsini,Francesca Monteleone,Nicola Zambrano,Gabriella Fontanini,Adele Servadio,Giuseppe Pignataro,Lucia Grumetto,Antonio Lavecchia,Dario Bruzzese,Antonino Iaccarino,Giancarlo Troncone,Bianca Maria Veneziani,Nunzia Montuori,Sabino De Placido,Roberto Bianco
DOI: https://doi.org/10.1038/s41598-017-10062-1
IF: 4.6
2017-08-24
Scientific Reports
Abstract:The urokinase-type plasminogen activator receptor (uPAR) is a GPI-anchored cell membrane receptor that focuses urokinase (uPA) proteolytic activity on the cell surface. Its expression is increased in many human cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and correlates with a poor prognosis and early invasion and metastasis. uPAR is able to control, through a cross-talk with tyrosine kinase receptors, the shift between tumor dormancy and proliferation, that usually precedes metastasis formation. Therefore, we investigated the role of uPAR expression in RAS mutated NSCLC and CRC cells. In this study we provided evidence, for the first time, that RAS mutational condition is functionally correlated to uPAR overexpression in NSCLC and CRC cancer cell lines and patient-derived tissue samples. Moreover, oncogenic features related to uPAR overexpression in RAS mutated NSCLC and CRC, such as adhesion, migration and metastatic process may be targeted, in vitro and in vivo, by new anti-uPAR small molecules, specific inhibitors of uPAR-vitronectin interaction. Therefore, anti-uPAR drugs could represent an effective pharmacological strategy for NSCLC and CRC patients carrying RAS mutations.
multidisciplinary sciences